PODD Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of 14.25% compared to Insulet's net margin of 8.28%. Insulet's return on equity of 49.55% beat Globus Medical's return on equity of 2.27%.

Insulet has a consensus price target of $285.63, signalling upside risk potential of 7.16%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 14.04%. Given that Globus Medical has higher upside potential than Insulet, analysts believe Globus Medical is more attractive than Insulet.

Insulet has a beta of 1.209, which suggesting that the stock is 20.859% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $543.9M, which are smaller than Globus Medical quarterly revenues of $625.7M. Insulet's net income of $77.5M is higher than Globus Medical's net income of $51.8M. Notably, Insulet's price-to-earnings ratio is 45.64x while Globus Medical's PE ratio is 123.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.27x versus 4.57x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of 14.25% compared to Insulet's net margin of 9.79%. Insulet's return on equity of 49.55% beat Haemonetics's return on equity of 13.51%.

Insulet has a consensus price target of $285.63, signalling upside risk potential of 7.16%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 46.87%. Given that Haemonetics has higher upside potential than Insulet, analysts believe Haemonetics is more attractive than Insulet.

Insulet has a beta of 1.209, which suggesting that the stock is 20.859% more volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $543.9M, which are larger than Haemonetics quarterly revenues of $345.5M. Insulet's net income of $77.5M is higher than Haemonetics's net income of $33.8M. Notably, Insulet's price-to-earnings ratio is 45.64x while Haemonetics's PE ratio is 31.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.27x versus 2.85x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of 14.25% compared to Insulet's net margin of 20.32%. Insulet's return on equity of 49.55% beat LeMaitre Vascular's return on equity of 13.37%.

Insulet has a consensus price target of $285.63, signalling upside risk potential of 7.16%. On the other hand LeMaitre Vascular has an analysts' consensus of $98.78 which suggests that it could grow by 7.22%. Given that LeMaitre Vascular has higher upside potential than Insulet, analysts believe LeMaitre Vascular is more attractive than Insulet.

Insulet has a beta of 1.209, which suggesting that the stock is 20.859% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.933, suggesting its less volatile than the S&P 500 by 6.665%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.7% to investors and pays a quarterly dividend of $0.16 per share. Insulet pays -- of its earnings as a dividend. LeMaitre Vascular pays out 41.35% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Insulet quarterly revenues are $543.9M, which are larger than LeMaitre Vascular quarterly revenues of $54.8M. Insulet's net income of $77.5M is higher than LeMaitre Vascular's net income of $11.1M. Notably, Insulet's price-to-earnings ratio is 45.64x while LeMaitre Vascular's PE ratio is 50.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.27x versus 9.79x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 14.25% compared to Insulet's net margin of -9.53%. Insulet's return on equity of 49.55% beat Tandem Diabetes Care's return on equity of -47.23%.

Insulet has a consensus price target of $285.63, signalling upside risk potential of 7.16%. On the other hand Tandem Diabetes Care has an analysts' consensus of -- which suggests that it could grow by 41.82%. Given that Tandem Diabetes Care has higher upside potential than Insulet, analysts believe Tandem Diabetes Care is more attractive than Insulet.

Insulet has a beta of 1.209, which suggesting that the stock is 20.859% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.425%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $543.9M, which are larger than Tandem Diabetes Care quarterly revenues of $244M. Insulet's net income of $77.5M is higher than Tandem Diabetes Care's net income of -$23.3M. Notably, Insulet's price-to-earnings ratio is 45.64x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 10.27x versus 2.75x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.